Acute Myeloid Leukemia (AML)
Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.
This study evaluated whether antibacterial prophylaxis effectively reduced the rate of infections overall for patients receiving intensive chemotherapy for relapsed/refractory AML.
Research using cancer cell lines demonstrated that supplementing standard epigenetic therapy with vitamin C enhanced the drug's antineoplastic action.
Patients with acute myeloid leukemia (AML) harboring mutations in the TP53 gene have worse complete remission rates and durations and overall survival regardless of age or the type of treatment received.
Telomere length is predictive for determining which children treated for AML are at highest risk for delayed recovery, a finding that may have significant implications for treatment-related morbidity and mortality.
Deep and durable remissions were produced by the combination of SGN-CD33A and hypomethylating agents among patients with acute myeloid leukemia (AML).
The FLT3 tyrosine kinase is the most frequent mutation found in AML, and targeting CDK6 with palbociclib may be an effective strategy against AML.
Combining birinapant with a p38 inhibitor is a promising therapeutic regimen for patients with acute myeloid leukemia (AML).
First-line monotherapy with low-dose gemtuzumab ozogamicin significantly improved overall survival compared with best supportive care.
A simple blood test can identify post-chemo patients with the NPM1 gene mutation.
Progress from myelodysplastic syndrome to AML is linked to the enzyme glycogen synthase kinase, and a molecular signature is found to predict clinical outcomes of patients with MDS.
Results of a phase 3 randomized trial support high intensity conditioning with myeloablative regimens prior to allogeneic stem cell transplantation as standard of care for patients with acute myeloid leukemia.
Immunophenotypic expression profiles can provide a tool to discriminate cohorts of young patients with acute myeloid leukemia (AML) that have a high relapse probability.
An oral formulation of azacitidine was safe and clinically active in patients with acute myeloid leukemia (AML), according to results presented at the 57th American Society of Hematology Annual Meeting.
For patients with refractory acute myeloid leukemia (AML), employment of allogeneic stem cell transplantation may be a valid treatment strategy.
Although a fourth chemotherapy course may benefit younger patients with poor-risk acute myeloid leukemia, those with good and standard risk demonstrated little survival benefit from the additional course.
Addition of Midostaurin Significantly Improved Event-Free and Overall Survival in Some Patients With Acute Myeloid LeukemiaDecember 06, 2015
The addition of midostaurin, a multi-target protein kinase inhibitor, to to standard chemotherapy for AML has been associated with increased survival.
Biologic Age Need Not be a Limiting Factor for Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML)November 25, 2015
More than 40% of older patients with AML can remain in long-term cancer remission through a modified, less aggressive approach to donor stem cell transplantation, according to the results of a phase 2 study.
A molecule isolated from sea sponges and later synthesized can halt the growth of cancerous cells, opening the door to a new treatment for leukemia.
A new study reveals that insurance status, marital status, and county-level income may affect survival for younger patients with AML, indicating that efforts are needed to address social factors that impact critical aspects of health.
Targeting exhausted immune cells may change the prognosis for patients with AML relapse after a stem cell transplant, according to a recent study.
Genetic mutations identified during remission of leukemia may help predict risk of relapse, survivalSeptember 11, 2015
Even though potentially curative therapy is now available for many patients with AML, the therapy is expensive and is associated with significant side effects. This study explained that identifying patients at high risk for relapse would be helpful clinically.
Early discharge after intensive acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) can reduce both costs and use of intravenous antibiotics, according to a new study.
Intravenous busulfan plus cyclophosphamide may be a valid and efficient alternative for patients with refractory acute myeloid leukemia.
Transitioning a long-standing intensive chemotherapy regimen for acute myeloid leukemia (AML) to the outpatient setting is safe and feasible.
Antibiotic prophylaxis with contrimoxazole/colistin similar to ciprofloxacin in acute myeloid leukemiaApril 06, 2015
Antibiotic prophylaxis regimen used from cotrimoxazole/colistin (COT/COL) to ciprofloxacin (CIP) in patients with acute myeloid leukemia (AML).
Presence of this protein indicates a likely toxicity effect associated with chemotherapy in acute myeloid leukemia (AML).
An oral targeted agent has shown encouraging activity and limited side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML), according to research.
Survival rates for patients who relapse in their battle with acute myeloid leukemia may benefit from therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.
Combination therapy effective for patients with higher-risk myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)January 05, 2015
Combined treatment with azacitidine and lenalidomide may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia.
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Recurrence Score Appears To Be Driving Personalized Treatment for Breast Cancer
- Smoking-related Cancer Deaths Highest in Southern United States
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|